On this site you can find recent news about Profil. You can read more about Profil and our work as clinical research organization. Furthermore, we will discuss interesting topics that are of high interest to pharmaceutical or technology companies innovating in the diabetes field.
For any questions or comments, please feel free to contact us using the contact button on the right.
January 7, 2021
Impact of COVID-19 on clinical trials In December 2019, China was affected by several cases of what was considered a fatal viral pneumonia (1). The numbers of affected patients were exponentially
December 17, 2020
Dear all, Greetings from Germany! I am happy to share with you the newest edition of "Profil World" - our newsletter filled with information about clinical research in diabetes and obesity. Profil
December 1, 2020
The β3‐adrenoceptor (β3-AR) was initially an attractive target for several pharmaceutical companies due to its high expression in rodent adipose tissue, where its activation resulted in decreased
November 17, 2020
Once-weekly basal insulin icodec treatment may offer more convenience in people with type 2 diabetes and may improve outcomes. Molecular and biological properties of once-weekly insulin icodec and
November 4, 2020
The landmark trials DCCT/EDIC trials show how important good glycaemic control is for the prevention of late complications in type 1 diabetes (T1D). According to the American Diabetes Association
October 13, 2020
Dear all, Greetings from Germany! I am happy to share with you the newest edition of "Profil World" - our newsletter filled with information about clinical research in diabetes and obesity. On-demand
September 21, 2020
Profil continues the successful series of scientific online seminars. On October 7th, 2020 at 4 PM CEST we will air our free online seminar. The session is presented by Dr. Lars Bochmann, Director
September 8, 2020
The euglycemic, hyperinsulinemic glucose clamp is the gold standard for the determination of pharmacokinetic and pharmacodynamic (PK/PD) effects of (new) anti-diabetic drugs, in particular insulins.